Evidence map›Paper›PMID 41020640›Full record

ArticleJournal of veterinary pharmacology and therapeutics2026

The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates.

Mark G Papich, Lacie A Gunnett, Marilyn N Martinez

Abstract read
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark G PapichCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Lacie A GunnettZoetis, Kalamazoo, Michigan, USA.
Marilyn N MartinezCenter for Veterinary Medicine, US Food and Drug Administration, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0002-4512-853X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fluoroquinolone antimicrobial agents, enrofloxacin and marbofloxacin, were approved in the United States for cats in 1990 and 2001, respectively. In 2023, revised breakpoints for testing isolates from dogs were published. These canine breakpoints are discordant with the current feline breakpoints. This study was aimed at suggesting new feline breakpoints using a pharmacokinetic-pharmacodynamic (PK-PD) approach and new pharmacokinetic data. The PK-PD derived cutoff values (CO

Indexed as

Anti-Bacterial AgentsBacteriaCat DiseasesFluoroquinolonesAnimalsCatsDrug Resistance, BacterialEnrofloxacinMicrobial Sensitivity TestsAnti-Bacterial AgentsEnrofloxacinFluoroquinolonesmarbofloxacinantimicrobialcatsenrofloxacinmarbofloxacinsusceptibility testing

Identifiers

PMID41020640
PMCPMC12968511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.